BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 8930174)

  • 1. Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin.
    Brown NJ; Ryder D; Gainer JV; Morrow JD; Nadeau J
    J Pharmacol Exp Ther; 1996 Nov; 279(2):703-12. PubMed ID: 8930174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration of flow-induced dilatation in mesenteric resistance arteries of L-NAME treated rats and its partial association with induction of cyclo-oxygenase-2.
    Henrion D; Dechaux E; Dowell FJ; Maclour J; Samuel JL; Lévy BI; Michel JB
    Br J Pharmacol; 1997 May; 121(1):83-90. PubMed ID: 9146891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostacyclin: its pathogenic role in essential hypertension and the class effect of ACE inhibitors on prostaglandin metabolism.
    Rodríguez-García JL; Villa E; Serrano M; Gallardo J; García-Robles R
    Blood Press; 1999; 8(5-6):279-84. PubMed ID: 10803488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secretory dysfunction of vascular endothelium limits the effect of angiotensin converting enzyme inhibitor quinapril on aggregation of erythrocytes in experimental hypertension.
    Korbut RA; Madej J; Adamek-Guzik T; Korbut R
    J Physiol Pharmacol; 2003 Sep; 54(3):397-408. PubMed ID: 14566078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differing effects of two angiotensin converting enzyme inhibitors, captopril and CI-906, on diuresis and the urinary excretion of kallikrein and prostaglandins in spontaneously hypertensive rats.
    Säynävälammi P; Pörsti I; Nurmi AK; Seppälä E; Laitinen LA; Manninen V; Ylitalo P; Vapaatalo H
    Scand J Urol Nephrol Suppl; 1984; 79():23-7. PubMed ID: 6089314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
    Wallis EJ; Ramsay LE; Hettiarachchi J
    Clin Pharmacol Ther; 1998 Oct; 64(4):439-49. PubMed ID: 9797801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of bradykinin by captopril during suppression of prostacyclin synthesis.
    Vandongen R; Tunney A; Barden A; Mahoney D
    Hypertension; 1982; 4(5):642-5. PubMed ID: 7049919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo endothelial interaction between ACE and COX inhibitors.
    Gryglewski RJ; Chlopicki S; Swies J
    Prostaglandins Leukot Essent Fatty Acids; 2005 Feb; 72(2):129-31. PubMed ID: 15626595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats.
    De Gennaro Colonna V; Rigamonti A; Fioretti S; Bonomo S; Manfredi B; Ferrario P; Bianchi M; Berti F; Muller EE; Rossoni G
    Eur J Pharmacol; 2005 Jun; 516(3):253-9. PubMed ID: 15963975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin.
    Brown NJ; Nadeau JH; Vaughan DE
    Thromb Haemost; 1997 Mar; 77(3):522-5. PubMed ID: 9066005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? new insights from proline-rich peptides of Bothrops jararaca.
    Ianzer D; Santos RA; Etelvino GM; Xavier CH; de Almeida Santos J; Mendes EP; Machado LT; Prezoto BC; Dive V; de Camargo AC
    J Pharmacol Exp Ther; 2007 Aug; 322(2):795-805. PubMed ID: 17475904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibition and smoking potentiate the kinin response to cardiopulmonary bypass.
    Pretorius M; McFarlane JA; Vaughan DE; Brown NJ; Murphey LJ
    Clin Pharmacol Ther; 2004 Oct; 76(4):379-87. PubMed ID: 15470338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACE inhibitor potentiation of bradykinin-induced venoconstriction.
    Hecker M; Blaukat A; Bara AT; Müller-Esterl W; Busse R
    Br J Pharmacol; 1997 Aug; 121(7):1475-81. PubMed ID: 9257930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
    Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects.
    Gainer JV; Morrow JD; Loveland A; King DJ; Brown NJ
    N Engl J Med; 1998 Oct; 339(18):1285-92. PubMed ID: 9791144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Volume-induced natriuresis in healthy women: renal metabolism of prostacyclin and thromboxane, and physiological role of prostanoids.
    Agnoli GC; Borgatti R; Cacciari M; Lenzi P; Marinelli M; Stipo L
    Prostaglandins Leukot Essent Fatty Acids; 2001 Feb; 64(2):95-103. PubMed ID: 11237476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary 6-keto-PGF1 alpha after captopril and indomethacin: possible contribution of PGI2 to the antihypertensive mechanism of ACE inhibitors.
    Minuz P; Degan M; Covi G; Lechi C; Velo GP; Lechi A
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():199-202. PubMed ID: 2988309
    [No Abstract]   [Full Text] [Related]  

  • 19. Captopril reverses the reduced vasodilator response to bradykinin in hypertensive pregnant rats.
    Resende AC; Pimentel AM; de Moura RS
    Clin Exp Pharmacol Physiol; 2004 Nov; 31(11):756-61. PubMed ID: 15566389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACE inhibitor and AT1 antagonist stimulate duodenal HCO3- secretion mediated by a common pathway - involvement of PG, NO and bradykinin.
    Aihara E; Kagawa S; Hayashi M; Takeuchi K
    J Physiol Pharmacol; 2005 Sep; 56(3):391-406. PubMed ID: 16204762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.